CARGENE BIOPHARMA

CARGENE BIOPHARMA is a small nucleic acid drug research and development company that focuses on fully leveraging the liver's inherent regenerative potential to provide innovative solutions for patients with limited treatment options. Our innovation stems from Dr. Torsten Wuestefeld’s QuartzTM target identification platform, a versatile in vivo functional genomic screening platform capable of generating a range of potential targets for liver diseases and other conditions. Our lead program is a first-in-class GalNAc-siRNA, which aims to improve liver function in patients with cirrhosis by promoting liver regeneration.